A lag in foundational research and looming geopolitical risks will weigh on China's bid to build a world-class biotechnology innovation ecosystem, even as the sector's overseas momentum remains strong, according to JPMorgan.
"In China, there is still some catching up to do in basic research, particularly in biological and pharmaceutical research," said Yang Huang, head of China healthcare research at JPMorgan, during an interview on Wednesday.
To meet the "ambitious goal" set in the country's...
AI Brief
Your highlights
This article is available on the publisher's site.